- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT01256450
Efficacy and Safety Study of Buprenorphine HCl Buccal Film in Subjects With Low Back Pain
A 12-Week, Placebo Controlled, Double Blind, Randomized Withdrawal Study to Evaluate the Efficacy and Safety of Buprenorphine HCl Buccal Film in Subjects With Moderate to Severe Chronic Low Back Pain
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
This is an enriched enrollment, randomized withdrawal study with an open label, dose-titration period followed by a randomized, double-blind, placebo-controlled treatment period of 12 weeks. During the double-blind treatment period, this study will evaluate the effectiveness of buprenorphine HCl buccal film versus placebo buccal film in treating CLBP in subjects.
Buprenorphine HCl buccal film is an oral transmucosal form of the opioid analgesic, buprenorphine hydrochloride, intended for application to the buccal mucosa. Buprenorphine is a synthetic opioid that is classified as a partial µ-receptor agonist and a Schedule III controlled substance in the United States.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 3
Kontakte und Standorte
Studienorte
-
-
Alabama
-
Birmingham, Alabama, Vereinigte Staaten, 35209
- Alabama Orthopaedic Center - Research
-
Mobile, Alabama, Vereinigte Staaten, 36608
- Coastal Clinical Research, Inc.
-
-
Arizona
-
Phoenix, Arizona, Vereinigte Staaten, 85023
- Arizona Research Center
-
-
California
-
Fresno, California, Vereinigte Staaten, 93710
- Neuro-Pain Medical Center
-
La Jolla, California, Vereinigte Staaten, 92037
- University of California, San Diego Medical Center, UCSD Center for Pain Medicine
-
Long Beach, California, Vereinigte Staaten, 90806
- Collaborative Neuroscience Network, Inc.
-
-
Florida
-
DeLand, Florida, Vereinigte Staaten, 32720
- Avail Clinical Research, LLC
-
Jupiter, Florida, Vereinigte Staaten, 33458
- Health Awareness, Inc.
-
Plantation, Florida, Vereinigte Staaten, 33317
- Gold Coast Research, LLC
-
Port Orange, Florida, Vereinigte Staaten, 32129
- Accord Clinical Research, LLC
-
-
Georgia
-
Marietta, Georgia, Vereinigte Staaten, 30060
- Taylor Research, LLC
-
-
Illinois
-
Bloomington, Illinois, Vereinigte Staaten, 61701
- Millennium Pain Center
-
-
Indiana
-
Evansville, Indiana, Vereinigte Staaten, 47714
- MediSphere Medical Research Center, LLC
-
-
Kansas
-
Leawood, Kansas, Vereinigte Staaten, 66211
- International Clinical Research Institute
-
-
Massachusetts
-
Watertown, Massachusetts, Vereinigte Staaten, 02472
- MedVadis Research Corporation
-
-
Nevada
-
Las Vegas, Nevada, Vereinigte Staaten, 89144
- Office of Stephen H. Miller, MD
-
-
New York
-
New York, New York, Vereinigte Staaten, 10022
- Research Across American
-
-
North Carolina
-
Raleigh, North Carolina, Vereinigte Staaten, 27612
- Wake Research Associates, LLC
-
Winston-Salem, North Carolina, Vereinigte Staaten, 27103
- The Center for Clinical Research, LLC
-
-
Pennsylvania
-
Altoona, Pennsylvania, Vereinigte Staaten, 16602
- Allegheny Pain Management
-
-
Texas
-
Austin, Texas, Vereinigte Staaten, 78731
- FutureSearch Trials of Neurology
-
El Paso, Texas, Vereinigte Staaten, 79902
- Southwest Urgent Care Center
-
-
Utah
-
Salt Lake City, Utah, Vereinigte Staaten, 84106
- Lifetree Clinical Research
-
West Jordan, Utah, Vereinigte Staaten, 84088
- Advanced Clinical Research
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Male or non-pregnant and non-nursing female aged 18 or older
- History of moderate to severe chronic low back pain for ≥3 months with a pain intensity ≥5 [11 point numerical rating scale] reported at the open-label titration period Day 0/1 visit following a washout period (opioids, nonsteroidal anti-inflammatory drugs [NSAIDs], and muscle relaxants) of approximately 12 to 24 hours
- Currently taking ≤60 mg oral morphine/day or equianalgesic dose of another opioid (including opioid naïve) for 1 week or longer
- Stable health, as determined by the Investigator, on the basis of medical history, physical examination, and screening laboratory results so as to comply with all study procedures
- Female subjects of childbearing potential must be using a recognized effective method of birth control
- Written informed consent obtained at Screening, prior to any procedure being performed
Exclusion Criteria:
- Reflex sympathetic dystrophy or causalgia (complex regional pain syndrome), acute spinal cord compression, cauda equina compression, acute nerve root compression, meningitis, and discitis
- Surgical procedure for back pain within 2 months prior to screening or nerve/plexus block within 4 weeks of screening
- Hypokalemia or clinically unstable cardiac disease, including: unstable atrial fibrillation, symptomatic bradycardia, unstable congestive heart failure, or active myocardial ischemia
- Corrected QT (QTc) interval of >450 milliseconds on the 12-lead electrocardiogram (ECG)
- History of long QT syndrome, or an immediate family member with this condition
- Diagnosis of moderate to severe hepatic impairment.
- History of severe emesis with opioids
- Clinically significant sleep apnea
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Vervierfachen
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: BEMA Buprenorphin
bukkal löslicher Buprenorphin-Film
|
buccal soluble film; applied to the buccal mucosa twice daily
Andere Namen:
|
Placebo-Komparator: BEMA Placebo
placebo buccal soluble film
|
buccal soluble film; applied to the buccal mucosa twice daily
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Change in Pain Intensity From Baseline to Week 12
Zeitfenster: Baseline, Week 12
|
Change in pain intensity = average of daily pain scores from the last 7 days prior to week 12 visit - average of daily pain scores for the last 7 days prior to randomization.
Average pain intensity over the last 24 hours was rated on an 11-point numeric rating scale (NRS) ranging from 0 (no pain) to 10 (worst pain imaginable).
|
Baseline, Week 12
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Wechsel vom Ausgangswert zu Woche 12 im Roland Morris-Fragebogen zur Behinderung
Zeitfenster: Ausgangswert, Woche 12
|
Die Probanden beurteilen die Behinderung aufgrund von Rückenschmerzen mithilfe des Roland Morris Disability Questionnaire (RMDQ), der aus 24 Angaben zur Behinderung besteht.
Der RMDQ-Score ist die Gesamtzahl der überprüften Elemente und reicht von 0 bis 24, wobei höhere Scores auf eine größere Behinderung hinweisen.
|
Ausgangswert, Woche 12
|
Change From Baseline in Pain Intensity Over Time Using NRS Scale
Zeitfenster: Baseline; Day 14, Day 28, Day 42, Day 56, Day 70, and Day 84
|
Change in pain intensity = average of daily pain scores from the last 7 days prior to each visit - average of daily pain scores for the last 7 days prior to randomization.
Average pain intensity over the last 24 hours was rated on an 11-point numeric rating scale (NRS) ranging from 0 (no pain) to 10 (worst pain imaginable).
|
Baseline; Day 14, Day 28, Day 42, Day 56, Day 70, and Day 84
|
Number of Participants With Response to Treatment as Assessed by an NRS Scale
Zeitfenster: Week 12
|
Responses are defined as the relative improvement in pain score at week 12 from baseline, calculated from ratings of average pain intensity over the last 24 hours on an 11-point numeric rating scale (NRS) ranging from 0 (no pain) to 10 (worst pain imaginable).
|
Week 12
|
Percentage of Participants With Treatment Failure in the Double-blind Treatment Phase (up to 12 Weeks)
Zeitfenster: Baseline to treatment failure or end of double-blind treatment phase (up to 12 weeks)
|
Treatment failure is defined as study discontinuation due to lack of efficacy or due to adverse event in the double-blind treatment phase.
|
Baseline to treatment failure or end of double-blind treatment phase (up to 12 weeks)
|
Subject Impression of Change in Pain Intensity From Baseline to Week 12 Using PGIC Scale
Zeitfenster: Baseline, Week 12
|
Subjects assessed changes in activity, limitations, symptoms, and overall quality of life related to their painful condition since beginning treatment using the Patient Global Impression of Change (PGIC), a balanced 7-point scale from 1 (no change or condition got worse) to 7 (a great deal better and considerable improvement that has made all the difference).
|
Baseline, Week 12
|
Change From Baseline to Week 12 in Treatment Satisfaction Using TSQM
Zeitfenster: Baseline, Week 12
|
The Treatment Satisfaction Questionnaire for Medication (TSQM) is a 14-item instrument used to assess the subject's satisfaction with the ability of the study medication to prevent or treat the condition of chronic low back pain (CLBP) for effectiveness, side effects, convenience, and global satisfaction.
Scores range from 0 to 100, where a higher score indicates less dissatisfaction (ie, greater satisfaction).
|
Baseline, Week 12
|
Change From Baseline to Week 12 in Subject's Overall Satisfaction With Study Drug
Zeitfenster: Baseline, Week 12
|
Subjects were asked to rate their overall satisfaction with their study drug on a 5-point scale ranging from 1 (poor) to 5 (excellent).
|
Baseline, Week 12
|
Change From Baseline to Week 12 in Investigator's Overall Satisfaction With Study Drug
Zeitfenster: Baseline, Week 12
|
Investigators rated their overall satisfaction with the study drug administered to a given subject on a 5-point scale ranging from 1 (poor) to 5 (excellent).
|
Baseline, Week 12
|
Use of Rescue Medication
Zeitfenster: Day 7, 14, 28, 42, 56, 70, 84, and 91 within double-blind treatment phase
|
Calculated from the use of rescue medication recorded in subject diary as the sum of all rescue medication tablets used in the last 7 days previous to the derived visit, divided by the number of days in this duration where the amount was reported.
|
Day 7, 14, 28, 42, 56, 70, 84, and 91 within double-blind treatment phase
|
Mitarbeiter und Ermittler
Ermittler
- Studienleiter: Andrew Finn, PharmD, BioDelivery Sciences International, Inc.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Schmerzen
- Neurologische Manifestationen
- Rückenschmerzen
- Schmerzen im unteren Rücken
- Physiologische Wirkungen von Arzneimitteln
- Depressiva des zentralen Nervensystems
- Agenten des peripheren Nervensystems
- Analgetika
- Agenten des sensorischen Systems
- Analgetika, Opioide
- Betäubungsmittel
- Narkotische Antagonisten
- Buprenorphin
Andere Studien-ID-Nummern
- BUP-301
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Schmerzen
-
Foundation IRCCS San Matteo HospitalAktiv, nicht rekrutierendGreater Trochanteric Pain Syndrome beider unteren ExtremitätenItalien
-
Gazi UniversityAbgeschlossenGesäß-Tendinitis | Greater Trochanteric Pain Syndrome beider unteren ExtremitätenTruthahn
-
Lawson Health Research InstituteNoch keine RekrutierungSchmerzen im unteren Rücken | Greater Trochanteric Pain Syndrome
-
C.R.Darnall Army Medical CenterUnbekanntGreater Trochanteric Pain SyndromeVereinigte Staaten
-
Guna S.p.aBeendetGreater Trochanteric Pain Syndrome | Pertrochantäre Fraktur | Gesäß-Tendinitis | GTPS - Greater Trochanteric Pain Syndrome | Sehnenerkrankung | GesäßmuskulaturItalien
-
Smith & Nephew, Inc.AbgeschlossenHüftschmerzen chronisch | Greater Trochanteric Pain SyndromeAustralien
-
NHS Greater Glasgow and ClydeNHS Research ScotlandRekrutierungGreater Trochanteric Pain SyndromeVereinigtes Königreich
-
Kutahya Health Sciences UniversityRekrutierungGreater Trochanteric Pain SyndromeTruthahn
-
Massachusetts General HospitalAbgeschlossenGreater Trochanteric Pain SyndromeVereinigte Staaten
-
Montefiore Medical CenterNoch keine RekrutierungGreater Trochanteric Pain SyndromeVereinigte Staaten
Klinische Studien zur Buprenorphine
-
Montefiore Medical CenterRekrutierungOpioidkonsumstörungVereinigte Staaten
-
Steve N. Caritis, MDEunice Kennedy Shriver National Institute of Child Health and Human Development...RekrutierungSchwangerschaft | OpiatsuchtVereinigte Staaten
-
Indivior Inc.Abgeschlossen
-
Friends Research Institute, Inc.National Institute on Drug Abuse (NIDA)Abgeschlossen
-
Orexo ABWorldwide Clinical TrialsAbgeschlossenOpioidbezogene Störungen | OpiatabhängigkeitVereinigte Staaten
-
CBT4CBT, LLCAbgeschlossen
-
Indivior Inc.Abgeschlossen
-
Duke UniversityNational Institute on Drug Abuse (NIDA); The Emmes Company, LLCAbgeschlossenOpioidkonsumstörungVereinigte Staaten
-
Psychiatric University Hospital, ZurichUnbekannt
-
Yale UniversityNational Institute on Drug Abuse (NIDA)AbgeschlossenOpiatabhängigkeitVereinigte Staaten